Amgen Hopes That Downgrading Nplate REMS Can Escape NCD
This article was originally published in The Pink Sheet Daily
Executive Summary
If FDA is potentially willing to downgrade the risk management plan for the immune thrombocytopenia treatment Nplate (romiplostim), CMS should drop the drug from consideration for a National Coverage Determination, the company argues.